Small Study of TT Vaccine
Phase 1
- Registration Number
- CTRI/2017/11/010448
- Lead Sponsor
- Biovaccines INDIA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Healthy Adult Subjects
Exclusion Criteria
NOT WILLING TO GIVE CONSENT
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion/percentage of subjects achieving seroconversion response against tetanus vaccine, 4 weeks after single booster doseTimepoint: Proportion/percentage of subjects achieving seroconversion response against tetanus vaccine, 4 weeks after single booster dose
- Secondary Outcome Measures
Name Time Method â?¢Incidence of solicited adverse events 7 days after the vaccine dose in the two treatment groupsTimepoint: 4 WEEKS